Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 17,703	$ 13,806
Accounts receivable, net of allowance for credit losses of $3,225 and $4,068 at 2021 and 2020, respectively	96,830	83,192
Inventories	45,443	38,151
Prepaid expenses	14,059	14,797
Income taxes receivable	9,911	9,675
Other current assets	5,109	6,227
TOTAL CURRENT ASSETS	189,055	165,848
PROPERTY, PLANT AND EQUIPMENT, net	110,952	115,293
RIGHT OF USE ASSETS	61,387	66,385
INTANGIBLES	8,139	8,583
GOODWILL	99,445	99,445
DEFERRED TAX ASSETS, net	70,462	72,775
OTHER ASSETS	41,413	40,250
TOTAL ASSETS	580,853	568,579
CURRENT LIABILITIES:
Accounts payable	29,726	23,028
Accrued payroll and related costs	20,833	26,526
Taxes other than payroll and income	5,931	6,556
Unearned revenues	7,765	5,457
Operating lease liabilities	12,342	11,437
Income taxes payable	6,502	8,347
Other current liabilities	7,683	8,399
TOTAL CURRENT LIABILITIES	90,782	89,750
LONG-TERM DEBT, net	188,636	259,433
LONG-TERM OPERATING LEASE LIABILITIES	49,286	56,108
DEFERRED COMPENSATION	39,101	39,145
DEFERRED TAX LIABILITIES, net	24,336	20,585
OTHER LONG-TERM LIABILITIES	27,711	27,985
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	0	0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 46,454,264 issued and 46,349,397 outstanding at 2021 and 44,796,252 issued and 44,572,801 outstanding at 2020	1,188	1,148
Additional paid-in capital	101,120	41,184
Retained earnings	68,349	50,456
Accumulated other comprehensive income (loss)	(10,133)	(7,200)
Treasury shares (at cost), 104,867 at 2021 and 223,451 at 2020	(4,075)	(14,075)
Total Core Laboratories N.V. shareholders' equity	156,449	71,513
Non-controlling interest	4,552	4,060
TOTAL EQUITY	161,001	75,573
TOTAL LIABILITIES AND EQUITY	$ 580,853	$ 568,579